Recursion Pharmaceuticals (NASDAQ:RXRX) Given New $5.00 Price Target at Morgan Stanley

Recursion Pharmaceuticals (NASDAQ:RXRX) had its target price lowered by Morgan Stanley from $8.00 to $5.00 in a research report released on Monday,Benzinga reports. The firm currently has an equal weight rating on the stock.

RXRX has been the topic of a number of other reports. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Finally, Needham & Company LLC dropped their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.00.

Recursion Pharmaceuticals Trading Up 1.6%

NASDAQ RXRX opened at $5.00 on Monday. Recursion Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -3.27 and a beta of 0.84. The company’s fifty day moving average price is $4.91 and its two-hundred day moving average price is $6.31.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the company posted ($0.39) earnings per share. As a group, research analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently modified their holdings of the company. Man Group plc acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $479,000. Rockefeller Capital Management L.P. increased its holdings in shares of Recursion Pharmaceuticals by 323.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company’s stock worth $1,906,000 after acquiring an additional 215,283 shares during the period. Invesco Ltd. increased its holdings in shares of Recursion Pharmaceuticals by 54.6% in the 4th quarter. Invesco Ltd. now owns 178,619 shares of the company’s stock worth $1,207,000 after acquiring an additional 63,068 shares during the period. Norges Bank acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $23,429,000. Finally, California State Teachers Retirement System increased its holdings in shares of Recursion Pharmaceuticals by 30.7% in the 4th quarter. California State Teachers Retirement System now owns 231,535 shares of the company’s stock worth $1,565,000 after acquiring an additional 54,449 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.